Osimertinib,Pemetrexed,Carboplatin,Cisplatin,gefitinib
AstraZeneca
['sclc', 'nsclc', 'flaura']
adding brief course of chemotherapy improved median pfs from 12m to 18m but these curves come together over time. no difference in survival. for #egfr nsclc, i don t feel this strategy changes soc. will need to see if the flaura2 data look fundamentally different. #asco23 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast, #ITYSL, #HereWeGo